The proposed compositions and methods for preparation thereof relate to pharmacology, medicine, veterinary science and pharmaceutical industry. The compositions can be used for preparing infusion solutions of antimicrobial (antibacterial and antifungal) preparations increasing therapeutic efficiency thereof. The compositions include nanostructured colloidal silica and are efficient when treating overwhelming sepsis of tested animals. The pharmaceutical compositions have a proven and significant clinically important potentiating impact on therapeutic efficiency of the infusion solution, when treating inflammatory diseases, in comparison with traditional solvents.

CS-doped SrO nanocomposite were successfully synthesized through co-precipitation route for bactericidal activities. Effect of CS doping on morphological features, optical properties, elemental composition and phase constitution on CS-doped SrO nanocomposite was analyzed. XRD analysis confirmed tetragonal and cubic structures of SrO nanoparticles and CS-doped SrO nanocomposite. UV-vis spectroscopy was used to obtain 4.19 eV of SrO nanoparticles while emission spectra of doped SrO showed blueshift upon CS doping with multi-concentration. Interlayer d-spacing attained from HRTEM micrographs well matched with XRD d-spacing. Purity content of prepared nanostructures was measured with EDS analysis. Overall, 0.06:1 showed significant antibacterial activity against both Gram +ve and -ve bacterial isolates. Thus, CS-doped SrO nanocomposite can be used in modem medicine as an alternative antibacterial to overcome the development of resistance to antibiotics.

CS-doped SrO nanocomposite were successfully synthesized through co-precipitation route for bactericidal activities. Effect of CS doping on morphological features, optical properties, elemental composition and phase constitution on CS-doped SrO nanocomposite was analyzed. XRD analysis confirmed tetragonal and cubic structures of SrO nanoparticles and CS-doped SrO nanocomposite. UV-vis spectroscopy was used to obtain 4.19 eV of SrO nanoparticles while emission spectra of doped SrO showed blueshift upon CS doping with multi-concentration. Interlayer d-spacing attained from HRTEM micrographs well matched with XRD d-spacing. Purity content of prepared nanostructures was measured with EDS analysis. Overall, 0.06:1 showed significant antibacterial activity against both Gram +ve and -ve bacterial isolates. Thus, CS-doped SrO nanocomposite can be used in modem medicine as an alternative antibacterial to overcome the development of resistance to antibiotics.

A cocrystal having the formula LiX.aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions.

A cocrystal having the formula LiX.aM, or a solvate or hydrate thereof, wherein X is a conjugate base of an organic acid, M is a neutral organic molecule, and a is from 0.5 to 4, pharmaceutical compositions comprising such cocrystals, cocrystal solvates, or cocrystal hydrates, and methods of preparing such cocrystals, cocrystal solvates, or cocrystal hydrates, and such pharmaceutical compositions.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

Provided herein are pharmaceutically acceptable sodium thiosulfate and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-purgeable organic carbon in a sodium thiosulfate-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium thiosulfate. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium thiosulfate.

The present invention concerns a package comprising an acidic citrate containing concentrate, an acidic citrate containing concentrate (or acidic citrate containing solution), and a system wherein the acidic citrate containing concentrate is included for providing a dialysis treatment. The acidic citrate containing concentrate contains citric acid and citrate in a molar ratio of 75:25 to 85:15, and has a pH of between 2 and 3.

The present invention concerns a package comprising an acidic citrate containing concentrate, an acidic citrate containing concentrate (or acidic citrate containing solution), and a system wherein the acidic citrate containing concentrate is included for providing a dialysis treatment. The acidic citrate containing concentrate contains citric acid and citrate in a molar ratio of 75:25 to 85:15, and has a pH of between 2 and 3.

The present invention concerns a package comprising an acidic citrate containing concentrate, an acidic citrate containing concentrate (or acidic citrate containing solution), and a system wherein the acidic citrate containing concentrate is included for providing a dialysis treatment. The acidic citrate containing concentrate contains citric acid and citrate in a molar ratio of 75:25 to 85:15, and has a pH of between 2 and 3.